RxDoctor Payments Data

George Stokes, MD

Family Medicine · Cleveland, TXNPI 1003824509

Payments from drug & device makers

$13,254in general payments, 2019–2025

Across 702 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$861
  • AbbVie$698
  • Pfizer$599
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$13,08999%
  • Education$1641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,254 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$487,045
Medicare patients
296
Services billed
27,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$194,580
MounjaroTirzepatide96$119,519
TrulicityDulaglutide75$85,091
FarxigaDapagliflozin Propanediol77$67,400
EliquisApixaban79$63,380
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$50,194
XareltoRivaroxaban49$39,119
JardianceEmpagliflozin32$36,192
LinzessLinaclotide39$32,009
GemtesaVibegron31$22,578
MyrbetriqMirabegron25$19,780
RybelsusSemaglutide15$18,114
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$17,741
Tresiba Flextouch U-200Insulin Degludec28$16,611
VascepaIcosapent Ethyl24$13,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,443$212,694157 claims
Lilly USA, LLCMounjaro, Trulicity$861$204,610171 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,131$81,035107 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,824$67,935105 claims
PfizerEliquis$599$63,38079 claims
Johnson & JohnsonXarelto$567$39,11949 claims
Boehringer IngelheimJardiance$356$36,19232 claims
AbbVieLinzess$698$32,00939 claims
Sumitomo Pharma America, Inc.Gemtesa$190$22,57831 claims
Astellas Pharma US IncMyrbetriq$205$19,78025 claims
NovartisEntresto$57$13,75129 claims
MerckJanuvia$54$8,01014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →